Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription 18.05.2026 1 AJR Am J Roentgenol 1 Ann Thorac Surg 2 Arch Bronconeumol 1 BMC Cancer 2 Cancer 1 Cancer Cell 1 Cancer Lett 1 Cancer Sci 1 Carcinogenesis 1 Chest 3 Clin Lung Cancer 2 Eur J Cancer 8 Eur J Cardiothorac Surg 1 Int J Cancer 1 J Clin Oncol 2 J Comput Assist Tomogr 2 J Natl Cancer Inst 7 J Thorac Oncol 3 JAMA Oncol 18 Lung Cancer 1 Lung Cancer (Auckl) 1 Nat Genet 2 Oncologist 2 PLoS One 1 Science 3 Thorax

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. GUNDERMAN PR
   The VERITAS Trial and the Future of Transthoracic Biopsy: A Call to Action for Radiologists.
   AJR Am J Roentgenol. 2026;226:e2534133.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

2. SERVAIS EL
   Conversion, Judgment, and Priorities in Post-Induction Lung Cancer Surgery.
   Ann Thorac Surg. 2026 May 6:S0003-4975(26)00428.
   PubMed        
   
   

   
   Arch Bronconeumol

3. DZIEDZIC R, Kanyion P, Kon B, Kruk M, et al
   Low-dose Computed Tomography Lung Cancer Screening Participants Show Improved 10-year Survival Compared With Matched Controls: A Case-Control Study.
   Arch Bronconeumol. 2026 Mar 26:S0300-2896(26)00115.
   PubMed         Abstract available
   
   
4. MONCUSI A, Buron A, Lugon G, Macia F, et al
   Risk Perception and Intention to Quit Smoking Among High-Risk Participants Enrolled in a European Lung Cancer Screening Trial in Spain.
   Arch Bronconeumol. 2026 Apr 26:S0300-2896(26)00165.
   PubMed        
   
   

   
   BMC Cancer

5. CUI A, Tian Y, Chen H, Shi L, et al
   Study on the anti-lung cancer effects of Gracillin from Reineckia carnea by targeting STC1.
   BMC Cancer. 2026 May 14. doi: 10.1186/s12885-026-16180.
   PubMed         Abstract available
   
   

   
   Cancer

6. JIN H, Wang Y, Zhang Y, Wu Y, et al
   PD-L1 expression is associated with inferior outcomes independent of EGFR subtype in advanced non-small cell lung cancer with uncommon EGFR mutations treated with first-line second-generation EGFR-tyrosine kinase inhibitors.
   Cancer. 2026;132:e70460.
   PubMed         Abstract available
   
   
7. PATEL SA, Heald JL, Nead M, Singer B, et al
   The American Cancer Society National Lung Cancer Roundtable strategic plan: Challenges in clinical guideline recommendations for biomarker testing in lung cancer.
   Cancer. 2026;132:e70384.
   PubMed         Abstract available
   
   

   
   Cancer Cell

8. MA Y, Xue J, Gao F, Yang Y, et al
   JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1(G2032R) resistance mutation in NSCLC: The first-in-human phase 1 trial.
   Cancer Cell. 2026;44:983-994.
   PubMed         Abstract available
   
   

   
   Cancer Lett

9. WANG D, Xiao C, Fan T, Deng Z, et al
   GAB3 suppresses lung adenocarcinoma progression by inhibiting the MAPK signaling and potentiating CD8(+) T cell immunity.
   Cancer Lett. 2026;651:218532.
   PubMed         Abstract available
   
   

   
   Cancer Sci

10. SHIMIZU J, Nishio M, Ohashi K, Osoegawa A, et al
    Atezolizumab + Chemotherapy in Older Patients With Lung Cancer in Japan.
    Cancer Sci. 2026 May 14. doi: 10.1111/cas.70411.
    PubMed         Abstract available
    
    

    
    Carcinogenesis

11. WANG Y, Wu Y, Zheng S, Yan X, et al
    Stromal NNMT overexpression as an independent prognostic biomarker in lung adenocarcinoma and breast carcinoma.
    Carcinogenesis. 2026;47:bgag020.
    PubMed         Abstract available
    
    

    
    Chest

12. WISNIVESKY JP, Veluswamy R
    Beyond Tobacco: Identifying Lung Cancer Risk Among Individuals Who Have Never Smoked.
    Chest. 2026;169:1174-1175.
    PubMed        
    
    

    
    Clin Lung Cancer

13. BALDOTTO C, Mascarenhas E, Gelatti ACZ, Reis TV, et al
    Staging Modalities in Non-Small Cell Lung Cancer: Evidence-Based Guideline and Systematic Review by the Brazilian Group of Thoracic Oncology.
    Clin Lung Cancer. 2026;27:11-22.
    PubMed         Abstract available
    
    
14. MITOME N, Hamada A, Wakabayashi M, Uozumi T, et al
    A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI).
    Clin Lung Cancer. 2026;27:5-10.
    PubMed         Abstract available
    
    
15. MANSOORIAN S, Lehmann J, Kasmann L, Gaus R, et al
    Exploring Thoracic Radiotherapy in Metastatic NSCLC: A Retrospective Review in the Era of Immunotherapy and Targeted Therapies.
    Clin Lung Cancer. 2026;27:54-64.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

16. LI W, Li W
    Letter Re: Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the ISTOP study.
    Eur J Cancer. 2026;241:116765.
    PubMed        
    
    
17. GEMELLI M, Sala L, Morabito A, Sforza V, et al
    Response to Letter Re: Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the ISTOP study.
    Eur J Cancer. 2026;241:116766.
    PubMed        
    
    

    
    Eur J Cardiothorac Surg

18. WANG Z, Gonzalez-Rivas D, Yu J, Bao Y, et al
    Uniportal Robotic-Assisted Sleeve Resections in a High-Volume Centre: Technique and Results.
    Eur J Cardiothorac Surg. 2026;68.
    PubMed         Abstract available
    
    
19. SIHOE ADL
    Multiport Versus Single-Port Video-Assisted Thoracic Surgery for Pulmonary Resection.
    Eur J Cardiothorac Surg. 2026;68.
    PubMed         Abstract available
    
    
20. CECCARELLI I, Durand M, Seguin Givelet A
    Lymphadenectomy and Upstaging in Thoracic Oncology: A Narrative Review.
    Eur J Cardiothorac Surg. 2026;68.
    PubMed         Abstract available
    
    
21. KIM HK
    Neoadjuvant Chemoimmunotherapy Followed by Surgery for Non-Small Cell Lung Cancer: Current Evidence and Unmet Needs.
    Eur J Cardiothorac Surg. 2026;68.
    PubMed         Abstract available
    
    
22. KWON J, Lee J
    Beyond Tumour Size: The Impact of Spread Through Air Spaces and Pleural Invasion on Surgical Strategy for Early-Stage Non-Small Cell Lung Cancer.
    Eur J Cardiothorac Surg. 2026;68.
    PubMed         Abstract available
    
    
23. CHANG ATC, Cho CSY, Chan JWY, Liu W, et al
    Post-Transbronchial Microwave Ablation Bronchopleural Fistula-A Case Series and Unique Insight.
    Eur J Cardiothorac Surg. 2026;68.
    PubMed         Abstract available
    
    
24. LEE JH, Choi J, Kang EJ, Gu BM, et al
    Single-Port Robotic Pulmonary Resection for Non-Small-Cell Lung Cancer After Neoadjuvant Chemoimmunotherapy.
    Eur J Cardiothorac Surg. 2026;68.
    PubMed         Abstract available
    
    
25. GONZALEZ-RIVAS D, Bosinceanu ML, Li C, Hu Y, et al
    First Transcontinental Single Port Robotic Thoracic Surgery.
    Eur J Cardiothorac Surg. 2026;68.
    PubMed         Abstract available
    
    

    
    Int J Cancer

26. GAO Z, Yang L, Wang L
    Chemoimmunotherapy With or Without Thoracic Radiotherapy for Elderly Patients in Advanced Non-Small Cell Lung Cancer.
    Int J Cancer. 2026 May 12. doi: 10.1002/ijc.70551.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

27. LU S, Jia J, Ren K, Jia W, et al
    Multicenter Cohort Study of Original or Substitute Systemic Therapy With or Without Brain Radiotherapy for Extensive-Stage Small Cell Lung Cancer With Brain-Only Progression After First-Line Treatment.
    J Clin Oncol. 2026 May 14:JCO2502536. doi: 10.1200/JCO-25-02536.
    PubMed         Abstract available
    
    

    
    J Comput Assist Tomogr

28. WANG G, Ren CJ, Shi YB, Miao HM, et al
    CT-Guided Anchored Needle Versus Hook-Wire Localization for Pulmonary Nodules: A Meta-Analysis.
    J Comput Assist Tomogr. 2026;50:448-453.
    PubMed         Abstract available
    
    
29. LONG Y, Li Y, Lin L, He C, et al
    Predicting Visceral Pleural Invasion in Part-Solid and Solid Nodules Using CT Features: A Systematic Review, Meta-Analysis, and Independent Cohort Validation.
    J Comput Assist Tomogr. 2026;50:426-433.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

30. SCHRAM AM, Yang SR, Kahn G, Velasco R, et al
    NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer.
    J Natl Cancer Inst. 2026;118:847-855.
    PubMed         Abstract available
    
    
31. MELOSKY B, Juergens RA, Chu QSC, Cheema P, et al
    Targeting common EGFR mutations in non-small cell lung cancer: a review of global phase 3 trials of third-generation inhibitors.
    J Natl Cancer Inst. 2026;118:789-810.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

32. KATSUMATA S, Kamigaichi A, Akamine T, Isaka M, et al
    Segmentectomy versus lobectomy in non-small-cell lung cancer with pathologically invasive features: a post-hoc supplementary analysis of a multicenter, Phase 3 trial JCOG0802/WJOG4607L.
    J Thorac Oncol. 2026 May 11:103916. doi: 10.1016/j.jtho.2026.103916.
    PubMed         Abstract available
    
    
33. D'ANGELILLO RM, Ramella S
    Heart-Sparing Radiotherapy in Patients With Lung Cancer.
    J Thorac Oncol. 2026;21:103612.
    PubMed        
    
    
34. ERASMUS JJ, Vlahos I
    Advances in Radiological Imaging for Thoracic Oncology: A 20-Year Perspective.
    J Thorac Oncol. 2026;21:103563.
    PubMed         Abstract available
    
    
35. TAFENZI HA, Essadi I, Belbaraka R
    Lung Cancer in Morocco.
    J Thorac Oncol. 2026;21:103561.
    PubMed         Abstract available
    
    
36. TUMINELLO S, Joyama Y, Taioli E
    Genetic Predisposition to Lung Cancer Is Modulated by Sex, Smoking, and Ancestry.
    J Thorac Oncol. 2026;21:103559.
    PubMed        
    
    
37. DREVET G, Kalson L, Mange L, Galateau-Salle F, et al
    Moving Beyond Morphology: Toward a Morpho-Molecular Classification of Pleural Mesothelioma.
    J Thorac Oncol. 2026;21:103551.
    PubMed         Abstract available
    
    
38. GUO H, Wang Y, Diao M, Han R, et al
    Bispecific T-cell Engager (CD3 x EGFR)-Based Triplet Therapy Unlocks CD40/CD40L Crosstalk to Revert Immunosuppression in Third-Generation EGFR-Tyrosine Kinase Inhibitor-Refractory NSCLC.
    J Thorac Oncol. 2026;21:103607.
    PubMed         Abstract available
    
    

    
    JAMA Oncol

39. XIAO W, Kong Q
    Generalizability and Fairness in Deploying AI for Lung Cancer Biomarker Prediction.
    JAMA Oncol. 2026 May 14. doi: 10.1001/jamaoncol.2026.1284.
    PubMed        
    
    
40. RAKAEE M, Kwiatkowski DJ
    Generalizability and Fairness in Deploying AI for Lung Cancer Biomarker Prediction-Reply.
    JAMA Oncol. 2026 May 14. doi: 10.1001/jamaoncol.2026.1287.
    PubMed        
    
    
41. HENLEY SJ, Adam EE, Kava CM, Wu M, et al
    Temporal Trends in Lung Cancer Cases Diagnosed at Early Stage.
    JAMA Oncol. 2026 May 14. doi: 10.1001/jamaoncol.2026.1199.
    PubMed         Abstract available
    
    

    
    Lung Cancer

42. SUN Z, Xin W, Tian Y, Lu S, et al
    Treatment patterns of elderly patients with limited-stage small-cell lung cancer in real-world data: A multicentre retrospective analysis.
    Lung Cancer. 2026;217:109450.
    PubMed         Abstract available
    
    
43. MUDUMBA R, Liu X, Jin S, Davis IJ, et al
    Comparative effectiveness of first-line targeted therapies in ALK-positive non-small cell lung cancer: real-world evidence of tyrosine kinase inhibitors.
    Lung Cancer. 2026;217:109451.
    PubMed         Abstract available
    
    
44. SHIRAISHI Y, Kishimoto J, Sugawara S, Mizutani H, et al
    Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.
    Lung Cancer. 2026;217:109447.
    PubMed         Abstract available
    
    
45. KO JJ, Blais N, Brade A, Clelland C, et al
    Consensus recommendations on surveillance and survivorship for patients with unresectable/stage IV non-small cell lung cancer after completing Immunotherapy: a Delphi study by Canadian experts.
    Lung Cancer. 2026;217:109455.
    PubMed         Abstract available
    
    
46. WEBER M, Raab AM, Schmitt KU, Busching G, et al
    Insights from a randomized controlled trial on a digital lifestyle intervention in non-small cell lung cancer survivors following inpatient rehabilitation.
    Lung Cancer. 2026;217:109433.
    PubMed         Abstract available
    
    
47. CHO BC, Lim SM, Lee SH, Kim DK, et al
    MORPHEUS-Lung: biomarkers and clinical response to atezolizumab + bevacizumab + stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer.
    Lung Cancer. 2027 Apr 16:109354. doi: 10.1016/j.lungcan.2026.109354.
    PubMed         Abstract available
    
    
48. ZHAO L, Li F, Zhu Z, Zhao J, et al
    Meta-analysis of cutaneous immune-related adverse events in NSCLC: Accounting for treatment heterogeneity and immortal time bias.
    Lung Cancer. 2026;216:109422.
    PubMed         Abstract available
    
    
49. MURATA S, Kashima J, Horinouchi H, Kishikawa S, et al
    Comparative analysis of therapeutic target protein expression in de novo and transformed small cell lung carcinomas using paired biopsy samples.
    Lung Cancer. 2026;216:109418.
    PubMed         Abstract available
    
    
50. ZHOU N, Tsui S, Toumbacaris N, Tan KS, et al
    Utilization of invasive mediastinal nodal staging and prevalence of occult nodal disease in patients with synchronous primary lung cancers.
    Lung Cancer. 2026;216:109420.
    PubMed         Abstract available
    
    
51. XU K, Tan B, Liang R, Liang J, et al
    DNA methylation biomarkers-based method for the differential diagnosis of multiple lung cancers.
    Lung Cancer. 2026;216:109415.
    PubMed         Abstract available
    
    
52. KENMOTSU H, Niho S, Tsuboi M, Wakabayashi M, et al
    Five-year overall survival in JCOG1205/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lung.
    Lung Cancer. 2026;216:109386.
    PubMed         Abstract available
    
    
53. HORNE A, Gomez-Randulfe I, Ford A, Milton R, et al
    Navigating controversies in stage III NSCLC: a multidisciplinary case discussion on evolving treatment paradigms.
    Lung Cancer. 2026;216:109411.
    PubMed         Abstract available
    
    
54. PASELLO G, Pigato G, Mulargiu C, Ferrarini F, et al
    Dissecting the prognostic role of metabolic markers in lung neuroendocrine Tumors: The MONET study.
    Lung Cancer. 2026;216:109404.
    PubMed         Abstract available
    
    
55. KLOK JM, Kaplan ZLR, Paats MS, Eijkelboom AH, et al
    Regional variations in molecular testing and treatment of patients with metastatic NSCLC in the Netherlands.
    Lung Cancer. 2026;216:109406.
    PubMed         Abstract available
    
    
56. CHIARI R, Russano M, Leva G, Emili R, et al
    A multicenter prospective study of single nucleotide polymorphisms in the PDCD1 (programmed cell death 1) gene in patients with metastatic lung adenocarcinoma treated with pembrolizumab.
    Lung Cancer. 2026;216:109383.
    PubMed         Abstract available
    
    
57. LIN JX, Yin K, Yan LX, Zhu Y, et al
    First case report of transformation of adenocarcinoma to adenosquamous carcinoma with giant-cell carcinoma harboring HER2 mutation after zongertinib (BI 1810631) resistance.
    Lung Cancer. 2026;216:108912.
    PubMed         Abstract available
    
    
58. RGN JY, Taylor S, Faivre-Finn C, Perry MB, et al
    New conversations in an old argument: Lessons learnt from the PIONEER randomised feasibility study in resectable stage III-N2 NSCLC.
    Lung Cancer. 2026;216:109387.
    PubMed         Abstract available
    
    
59. RUITER G, Le X, Soo RA, Yamamoto N, et al
    Emerging treatment strategies for HER2-mutant NSCLC: Striving for selectivity, efficacy, and tolerability.
    Lung Cancer. 2026;216:109378.
    PubMed         Abstract available
    
    

    
    Lung Cancer (Auckl)

60. LIU SM, Xie Z, Yan L, Jie GL, et al
    Exploratory Identification of Gene Copy Number Cut-Off for NGS-Based MET Amplification Assessment and Clinical Relevance to MET Inhibitor Outcomes in Non-Small-Cell Lung Cancer.
    Lung Cancer (Auckl). 2026;17:596080.
    PubMed         Abstract available
    
    

    
    Nat Genet

61. CALABRO L, Caruso FP, Covre A, Noviello TMR, et al
    Tumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study.
    Nat Genet. 2026;58:1100-1111.
    PubMed         Abstract available
    
    

    
    Oncologist

62. ROSNEV S, Klein K, Heukamp L, Lenk J, et al
    Liquid biopsy-based detection of acquired MET resistance enables sequential targeted therapy in MET fusion-positive NSCLC.
    Oncologist. 2026;31:oyag151.
    PubMed         Abstract available
    
    
63. DRILON A, Cho BC, Camidge DR, Nagasaka M, et al
    Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.
    Oncologist. 2026;31:oyag137.
    PubMed         Abstract available
    
    

    
    PLoS One

64. 
    Expression of Concern: Signaling Networks Associated with AKT Activation in Non-Small Cell Lung Cancer (NSCLC): New Insights on the Role of Phosphatydil-Inositol-3 kinase.
    PLoS One. 2026;21:e0349359.
    PubMed        
    
    
65. LOMLOY C, Yamashita PR, Termsaithong T, Laomettachit T, et al
    Uncovering the mechanisms of synergistic drug combinations in non-small cell lung cancer through metagene-based classification.
    PLoS One. 2026;21:e0343902.
    PubMed         Abstract available
    
    

    
    Science

66. RODRIGUEZ GE, Zhao Y, Nishiga Y, Peprah F, et al
    Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics.
    Science. 2026;392:eadx9954.
    PubMed         Abstract available
    
    

    
    Thorax

67. DICKSON JL, Rintoul RC
    Balancing benefits: trade-offs between selection criteria for lung cancer screening.
    Thorax. 2026 May 14:thorax-2026-224910. doi: 10.1136/thorax-2026-224910.
    PubMed        
    
    
68. GONNELLI F, Bonifazi M
    Lung cancer in idiopathic pulmonary fibrosis: do antifibrotics have a preventive effect?
    Thorax. 2026 May 12:thorax-2026-224808. doi: 10.1136/thorax-2026-224808.
    PubMed        
    
    
69. CHAN LT, Lau KKW, Orton CM, Temov K, et al
    Tool in lesion verification of shape-sensing robotic-assisted bronchoscopy with cone beam CT in sampling peripheral pulmonary nodules.
    Thorax. 2026;81:571-580.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum